Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216645
Status:
COMPLETED
Last Update Posted:
2011-05-17
First Post:
2005-09-13
Brief Title:
Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma Epithelial Ovarian Carcinoma Primary Carcinoma of Fallopian Tube Peritoneal Carcinoma Having Prior Platinum-Based Chemotherapy
Sponsor:
Janssen Pharmaceutical KK
Organization:
Janssen Pharmaceutical KK
Organization Data
Organization:
Janssen Pharmaceutical KK
Class:
INDUSTRY
Study ID:
CR004867
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Janssen Pharmaceutical KK
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None